| 28.06 17:49 | Aktien Schweiz gehen knapp behauptet in Wochenende |
| 28.06 13:36 | dpa-AFX: Roche-Medikamente Piasky und Vabysmo erhalten positive Empfehlungen |
| 28.06 13:31 | dpa-AFX: *ROCHE: VABYSMO ERHÄLT CHMP-EMPFEHLUNG FÜR DIE DRITTE INDIKATION |
| 28.06 13:15 | Press Release: Roche's Vabysmo gets CHMP -3- |
| 28.06 13:15 | Press Release: Roche's Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) |
| 28.06 13:15 | Press Release: Roche's Vabysmo gets CHMP -2- |
| 28.06 13:15 | dpa-AFX: GNW-Adhoc: Roche's Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) |
| 28.06 13:00 | Press Release: CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare, life-threatening blood condition |
| 28.06 13:00 | Press Release: CHMP recommends EU approval of -2- |
| 28.06 13:00 | dpa-AFX: GNW-Adhoc: CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare, life-threatening blood condition |
| 27.06 17:51 | Aktien Schweiz mit leichten Abgaben |
| 27.06 07:00 | dpa-AFX: GNW-Adhoc: Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection |
| 27.06 07:00 | Press Release: Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection |
| 27.06 07:00 | Press Release: Roche expands access to cervical -2- |
| 26.06 17:48 | Aktien Schweiz erneut mit Abschlägen |
| 25.06 17:48 | Aktien Schweiz nach deutlichem Vortagesplus mit Abgaben |
| 25.06 07:24 | Roche erhält EU-Zulassung für Multiple-Sklerose-Mittel |
| 25.06 07:00 | Press Release: Roche's OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis |
| 25.06 07:00 | Press Release: Roche's OCREVUS subcutaneous -2- |
| 25.06 07:00 | dpa-AFX: GNW-Adhoc: Roche's OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis |
|
|
